KDR and neoplasm: Though, VEGFR2 shares with EGFR key intracellular partners such as SHC1, protein tyrosine kinase 2, and phospholipase C. EGFR-mutant lung adenocarcinoma patients who acquired EGFR-TKI treatment resistance may benefit from blocking VEGFR2 related angiogenesis and tumor growth.